pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,594 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1777Endpoints1386Fierce Biotech705BioSpace697BioPharma Dive524raps234onclive165fda recalls113
therapy area
allOncology12301Rare Disease3205Immunology2862Cardiology2733Hematology2177Pulmonology2138Vaccines1794
  • Infant botulism cases linked to premium formulas raise safety concerns
    Several infants fell ill with botulism after consuming infant formula from the premium brand ByHeart, and a second brand, Nara Organics, has also been implicated. Health officials say the outbreak…
    STAT · 4mo agoRegulatoryNegative↗ source
  • cAMPfield Therapeutics raises $180 million to develop oral IBD drug prifemilast
    cAMPfield Therapeutics, a California biotech, announced a $180 million Series A financing to advance its oral anti‑inflammatory candidate for inflammatory bowel disease. The investigational drug,…
    BioPharma Dive · 4mo agoDealPositive↗ source
← prev
page 78 of 104
next →
fda medwatch111
globenewswire health73
fda press59
Psychiatry & CNS1204
Ophthalmology1051
Pain777
Endocrinology & Metabolism775
Nephrology760
  • CMS recalculates 2026 Medicare Advantage star ratings, increasing program volatility and affecting $16 billion in bonuses
    Federal officials have issued a new memo that recalculates the quality ratings for 2026 Medicare Advantage plans. The change follows another lawsuit from insurers that contest lower star ratings,…
    STAT · 4mo agoRegulatoryNegative↗ source
  • FDA advisory panel backs Moderna seasonal mRNA flu vaccine after earlier controversy
    A Food and Drug Administration advisory committee unanimously endorsed Moderna’s seasonal mRNA flu vaccine on Thursday, after the product became the focus of controversy earlier this year when a se…
    STAT · 4mo agoRegulatoryPositive↗ source
  • Eli Lilly stops 340B discounts for hospitals that did not submit required claims data
    Eli Lilly has begun withdrawing the federally mandated 340B price discounts from a handful of hospitals that have failed to provide the comprehensive claims data the company requires. The move fol…
    STAT · 4mo agoRegulatoryNegative↗ source
  • FDA lifts opposition to Huntington’s disease gene therapy, clearing path for development
    The Readout Loud podcast this week highlighted a regulatory shift for a gene therapy aimed at Huntington’s disease. The Food and Drug Administration reversed its earlier opposition, removing a key…
    STAT · 4mo agoRegulatoryPositive↗ source
  • Biogen to acquire RayThera in up to $1 billion deal for immunology pipeline
    Biogen announced it will acquire RayThera, a startup founded in 2023, in a deal valued at up to $1 billion. The acquisition gives Biogen access to RayThera’s immunology pipeline, which includes th…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Pfizer CFO Dave Denton to leave; Denali Therapeutics sells $195 million FDA priority review voucher
    Pfizer announced that its chief financial officer Dave Denton will depart on Aug. 15 to take a role outside the pharmaceutical sector. He has been CFO since May 2022. In the interim, finance chief…
    BioPharma Dive · 4mo agoDealNeutral↗ source
  • Shingles vaccine linked to 24% lower dementia risk in nursing home residents, study shows
    A new study of elderly nursing home residents examined the effect of receiving at least one dose of the shingles vaccine Shingrix on dementia incidence over a four year period. The analysis found…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Biogen to acquire RayThera for up to $1 billion as J&J shifts focus away from obesity to cancer
    Biogen announced an agreement to purchase RayThera for as much as $1 billion, marking the company's second takeover this year. The deal expands Biogen's portfolio into RayThera's pipeline, though s…
    STAT · 4mo agoDealNeutral↗ source
  • New poll shows only half of U.S. adults can afford quality health care, with record-high concerns for next year
    A recent West Health-Gallup Affordability Index found that roughly 50% of American adults said they could pay for health care and still access quality services in the past year. The survey also re…
    STAT · 4mo agoNegative↗ source
  • Super-potent nitazene opioids linked to sharp rise in U.S. overdose deaths
    Synthetic opioids known as nitazenes, which can be up to forty times stronger than fentanyl, are increasingly being found mixed into other street drugs across the United States. The Centers for Di…
    STAT · 4mo agoNegative↗ source
  • Senate Democrats subpoena HHS for records on Trump-era vaccine policy overhaul
    Senate Democrats have launched an inquiry into the Trump administration’s overhaul of U.S. vaccine policy, asking the Department of Health and Human Services to turn over records by the following w…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Pfizer and Amgen target GLP-1 weight-loss market to rival Novo Nordisk and Eli Lilly
    The STATus Report video hosted by Alex Hogan discusses the growing GLP-1 weight-loss drug market. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have been on the market for a few years and are pop…
    STAT · 4mo agoNeutral↗ source
  • Cardiovascular biotech Kardigan raises $400M in IPO, fourth 2026 $400M+ offering
    Kardigan, a cardiovascular drug startup, priced a $400 million initial public offering on Wednesday, adding to a recent surge in large biotech offerings. The company becomes the fourth biotech in…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Eli Lilly stops 340B discounts for dozens of hospitals that did not submit claims data
    Eli Lilly has begun removing the federally mandated 340B price discounts for a few dozen hospitals that have not provided the required claims data. The company said the step follows a warning it is…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Former Senators Urge Congress to Prioritize Global Health as Strategic Diplomacy
    The authors, former U.S. senators, argue that improving global health must become a top priority for the United States, especially in light of recent outbreaks such as hantavirus and Ebola, which l…
    STAT · 4mo agoPositive↗ source
  • Patrick Soon-Shiong's pancreatic cancer claims lag behind reality, STAT reports
    STAT's Adam Feuerstein notes a wide gap between the outcomes promised by Patrick Soon-Shiong's pancreatic cancer therapies and the results that have actually been delivered. The columnist highlight…
    STAT · 4mo agoNegative↗ source
  • AI's rising electricity and water demand poses a public health risk, authors warn
    Two public-health scholars argue that the expanding use of artificial intelligence is creating a hidden strain on essential services such as electricity and water. They note that the massive data c…
    STAT · 4mo agoNegative↗ source
  • STAT Health Tech examines whether wearables benefit cardiovascular patients
    Mario Aguilar writes in a STAT Health Tech newsletter that the issue of wearables for people with cardiovascular disease is under review. The piece notes that researchers have been studying whether…
    STAT · 4mo agoNeutral↗ source
  • Cambrian’s experimental longevity drug shown to mimic exercise effects
    Cambrian Therapeutics reported early data on a new compound aimed at extending healthy lifespan by reproducing some benefits of physical activity. The preclinical studies described in the newslett…
    STAT · 4mo agoNeutral↗ source
  • Trump administration earmarks $700 million for mental health and addiction programs, experts say funds are existing grants
    The Trump administration announced a $700 million allocation for mental health and addiction initiatives. Health Secretary Robert F. Kennedy Jr. described the money as new investments, but behavio…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • FDA reverses stance, allows UniQure to file for accelerated approval of Huntington’s gene therapy AMT-130
    The Food and Drug Administration has changed its earlier position and now permits UniQure to submit a marketing application for its experimental Huntington’s disease gene therapy, AMT-130. The age…
    STAT · 4mo agoRegulatoryPositive↗ source
  • RFK Jr. announces $700 million mental-health funding, experts say money is from existing grants
    RFK Jr. announced a $700 million package aimed at mental health and addiction services, with a particular focus on addressing homelessness linked to severe, untreated mental illness. Behavioral he…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • DOJ settlement forces OhioHealth to change contracting, prompting hospitals to review payer agreements
    The Department of Justice and the Ohio attorney general announced a proposed antitrust settlement that requires nonprofit OhioHealth to stop using certain contracting practices that were said to ke…
    STAT · 4mo agoRegulatoryNeutral↗ source